ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2018
Treatment outcome of non-carbapenemase-producing carbapenem-resistant Klebsiella pneumoniae infections: a multicenter study in Taiwan.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 32 citations in OpenAlex.
- Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Scarless excision of an insertion sequence in the OmpK36 promoter restores meropenem susceptibility in a non-carbapenemase-producingEmerging microbes & infections · 2025Article
- Genomic Characterization and Resistance Mechanisms of Carbapenem-ResistantInternational journal of molecular sciences · 2025Article
- Mortality-related risk factors of carbapenem-resistant Enterobacteriaceae infection with focus on antimicrobial regimens optimization: a real-world retrospective study in China.BMC infectious diseases · 2025Article
- Clinical Characterization, Risk Factors, and Mortality in Patients with Carbapenem-Resistant HypervirulentInfection and drug resistance · 2025Article
- Clinical Outcomes and Risk Factors for Death in Critically Ill Patients with Carbapenem-ResistantInfection and drug resistance · 2024Article
- Investigation on the mechanisms of carbapenem resistance among the non-carbapenemase-producing carbapenem-resistantFrontiers in cellular and infection microbiology · 2024Article
- Comparative Meropenem Pharmacodynamics and Emergence of Resistance against Carbapenem-Susceptible Non-Carbapenemase-Producing and Carbapenemase-Producing Enterobacterales: A Pharmacodynamic Study in a Hollow-Fiber Infection Model.Antibiotics (Basel, Switzerland) · 2023Article
- Characterisation of Non-Carbapenemase-Producing Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Mortality-Related Risk Factors and Novel Antimicrobial Regimens for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review.Infection and drug resistance · 2022Review
- Increased Involvement ofHealthcare (Basel, Switzerland) · 2021Article
- Risk Factors for Mortality in Patients withInfection & chemotherapy · 2021Article
- IS26-mediated amplification of blaOXA-1 and blaCTX-M-15 with concurrent outer membrane porin disruption associated with de novo carbapenem resistance in a recurrent bacteraemia cohort.The Journal of antimicrobial chemotherapy · 2021Article
- Does Antimicrobial Therapy Affect Mortality of Patients with Carbapenem-ResistantMicroorganisms · 2020Article
- Tigecycline Therapy for Infections Caused by Extended-Spectrum β-Lactamase-ProducingAntibiotics (Basel, Switzerland) · 2020Article
- Mortality, clinical and microbiological response following antibiotic therapy among patients with carbapenem-resistantData in brief · 2020Article
- Appropriate Treatment for Bloodstream Infections Due to Carbapenem-ResistantOpen forum infectious diseases · 2019Article
- Rapid Nanopore Assay for Carbapenem-ResistantFrontiers in microbiology · 2019Article
- Emergence of a novel mobile colistin resistance gene, mcr-8, in NDM-producing Klebsiella pneumoniae.Emerging microbes & infections · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 9 institutions in 1 country.
Funding
Abstract
Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections are associated with high mortality, and experiences with its treatment are usually based on carbapenemase-producing strains. Non-carbapenemase-producing CRKP is of clinical significance, but relevant studies are lacking. This nationwide study aimed to evaluate the outcome of antimicrobial therapy in patients with non-carbapenemase-producing CRKP infections. Patients with non-carbapenemase-producing CRKP infections were enrolled from 16 hospitals during January 2013 to December 2014 in Taiwan. Carbapenem resistance was defined as reduced susceptibility with a minimum inhibitory concentration of ≥2 mg/L for imipenem or meropenem. The resistance mechanisms of CRKP isolates were analyzed, and the clinical data of these patients were collected retrospectively. Independent risk factors of 14-day morality were determined by Cox regression analysis. A total of 99 patients with non-carbapenemase-producing CRKP infections were enrolled, and 14-day mortality was 27.3%. Among 67 patients treated with appropriate antimicrobial therapy, most (n = 61) patients received monotherapy. The 14-day mortality was lower in patients treated with appropriate monotherapy (21.3%) than in those with inappropriate therapy (37.5%). The multivariate regression model identified monotherapy (hazard ratio [HR], 0.30; 95% confidence interval [CI], 0.13-0.71; P = 0.005) as protective factor, and APACHE II scores (HR, 1.09; 95% CI, 1.01-1.18; P = 0.022) as risk factor associated with 14-day mortality. Tigecycline, colistin, and carbapenem were the most commonly used drugs in monotherapy. This study provides evidence supporting the efficacy of monotherapy in the treatment of non-carbapenemase-producing CRKP infections, and provides a future target for antibiotics stewardship for CRKP infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.